The estimated Net Worth of Kimi Iguchi is at least $16.4 Milion dollars as of 2 January 2024. Ms. Iguchi owns over 1,642 units of Sage Therapeutics Inc stock worth over $527,513 and over the last 10 years she sold SAGE stock worth over $11,952,494. In addition, she makes $3,925,580 as Chief Financial Officer a Treasurer at Sage Therapeutics Inc.
Sign up
Ms. Iguchi SAGE stock SEC Form 4 insiders trading
Kimi has made over 31 trades of the Sage Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently she exercised 1,642 units of SAGE stock worth $2,233 on 2 January 2024.
The largest trade she's ever made was selling 28,153 units of Sage Therapeutics Inc stock on 23 April 2018 worth over $4,018,278. On average, Kimi trades about 3,398 units every 68 days since 2014. As of 2 January 2024 she still owns at least 70,429 units of Sage Therapeutics Inc stock.
You can see the complete history of Ms. Iguchi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kimi Iguchi biography
Kimi E. Iguchi serves as Chief Financial Officer, Treasurer of the Company. From 2011 to 2013, Ms. Iguchi provided financial consulting services to various companies. From 2008 to 2011, Ms. Iguchi served as the Chief Operating Officer, North America for Santhera Pharmaceuticals Holding AG. From 2004 to 2007, Ms. Iguchi held the role of Vice President of Finance at Cyberkinetics Neurotechnology Systems, Inc. From 1998 to 2004, Ms. Iguchi was the Senior Director of Financial Reporting and Analysis at Millennium Pharmaceuticals, Inc., and from 1996 to 1998 was the Senior Manager, External Reporting at Biogen, Inc. Ms. Iguchi currently serves on the board of directors for Disarm Therapeutics, Inc. From 1987 to 1995, Ms. Iguchi also worked as a business assurance manager at PricewaterhouseCoopers LLP. Ms. Iguchi received her B.A. in chemistry from Drew University and an M.B.A. from Northeastern University.
What is the salary of Kimi Iguchi?
As the Chief Financial Officer a Treasurer of Sage Therapeutics Inc, the total compensation of Kimi Iguchi at Sage Therapeutics Inc is $3,925,580. There are 4 executives at Sage Therapeutics Inc getting paid more, with Jeffrey Jonas having the highest compensation of $9,902,080.
How old is Kimi Iguchi?
Kimi Iguchi is 57, she's been the Chief Financial Officer a Treasurer of Sage Therapeutics Inc since 2016. There are 10 older and 6 younger executives at Sage Therapeutics Inc. The oldest executive at Sage Therapeutics Inc is Dr. Jeffrey M. Jonas, 68, who is the Chief Innovation Officer, Chair of the Science & Technology Forum and Director.
What's Kimi Iguchi's mailing address?
Kimi's mailing address filed with the SEC is C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE, MA, 02142.
Insiders trading at Sage Therapeutics Inc
Over the last 10 years, insiders at Sage Therapeutics Inc have traded over $190,046,458 worth of Sage Therapeutics Inc stock and bought 150,092 units worth $6,260,297 . The most active insiders traders include Kevin P Starr, Robert Nelsen a Michael F Cola. On average, Sage Therapeutics Inc executives and independent directors trade stock every 32 days with the average trade being worth of $256,667. The most recent stock trade was executed by Kimi Iguchi on 2 January 2024, trading 1,642 units of SAGE stock currently worth $2,233.
What does Sage Therapeutics Inc do?
sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.
What does Sage Therapeutics Inc's logo look like?
Complete history of Ms. Iguchi stock trades at Sage Therapeutics Inc
Sage Therapeutics Inc executives and stock owners
Sage Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Jeffrey Jonas,
President, Chief Executive Officer and Director -
Michael Cloonan,
Chief Operating Officer -
Stephen Kanes,
Chief Medical Officer -
Anne Cook,
Senior Vice President, General Counsel, Secretary -
Kimi Iguchi,
Chief Financial Officer, Treasurer -
Albert Robichaud,
Chief Scientific Officer -
Elizabeth Barrett,
Independent Director -
George Golumbeski,
Independent Director -
Dr. Jeffrey M. Jonas,
Chief Innovation Officer, Chair of the Science & Technology Forum and Director -
Kevin Starr,
Independent Chairman of the Board -
Michael Cola,
Independent Director -
James Frates,
Independent Director -
Steven Paul,
Independent Director -
Geno Germano,
Independent Director -
Asha Nayak,
Independent Director -
Anne Marie Cook,
Sr. VP, Gen. Counsel & Sec. -
Dr. Albert J. Robichaud Ph.D.,
Chief Scientific Officer -
Kimi E. Iguchi,
CFO & Treasurer -
Barry E. Greene,
Pres, CEO & Director -
Barry Greene,
Director -
Dr. Jim Doherty Ph.D.,
Chief Devel. Officer -
Dr. Amy Schacterle Ph.D.,
Sr. VP of R&D Strategy and Bus. Management -
Erin E. Lanciani,
Chief People & Experience Officer -
Helen Rubinstein,
Investor Relations Officer -
Matt Lasmanis,
Chief Technology & Innovation Officer -
Rock Ventures Ii, L.P.Third...,
-
Howard H Pien,
-
Thomas Anderson,
See Remarks -
Robert Nelsen,
Director -
Venture Fund Vii Lparch Ven...,
-
Rock Ventures Ii, L.P.Third...,
-
Laura Gault,
Chief Medical Officer -
Jessica Federer,
-
Christopher Benecchi,
Chief Business Officer